(Press-News.org) The most comprehensive analysis yet of the epigenetic modifications present in breast cancer has revealed potentially important new ways to detect and treat the disease, Belgian researchers have reported.
Epigenetics is a term used to describe modifications to the DNA molecule that affect way its code is translated into proteins. These changes include methylation, a form of chemical modification.
Although researchers knew epigenetics was important in cancer, information about its exact contribution to breast carcinogenesis was scant, Dr Sarah Dedeurwaerder, from Université Libre de Bruxelles, in Brussels, explained at the IMPAKT Breast Cancer Conference.
"Our goal was to assess the epigenetic differences between normal tissue and primary tumor samples on a genome-wide scale, similarly to what has been done for gene expression patterns," Dr Dedeurwaerder said. "Here, we provide a glimpse to what DNA methylation profiling of primary breast tumors might bring to our understanding of their biology and diversity… that should contribute to better management of breast cancer patients."
The researchers performed a comprehensive DNA methylation profile on two independent sets of frozen breast tissue samples: a 'main set' of 123 samples, and a 'validation set' of 125 samples.
Their first finding was two major sub-types of breast cancer, defined according to whether the cancer expresses receptors for estrogen, are widely epigenetically controlled. "When we performed a clustering analysis of our samples based on their DNA methylation profiles, tumors segregated naturally into two distinct groups," Dr Dedeurwaerder said.
The first group was mainly composed of estrogen receptor-negative tumors, and the second one of estrogen receptor-positive tumors. "This indicates that ER-negative and ER-positive tumors have very different methylation profiles," she said.
"Furthermore, when we looked at more than 400 genes whose expression is positively or negatively correlated to the expression of the ER gene, we showed a reverse correlation between methylation and expression status of the majority of these genes. This suggests that epigenetics is probably involved in the regulation of expression of genes playing an important role in the establishment of the two major phenotypes of breast cancer determined by ER status."
The analysis also revealed new information about new sub-types of breast cancer. The researchers showed that DNA methylation profiles enabled breast tumors to be classified in more groups than those currently defined.
"This is really the most interesting part of these data," Dr Dedeurwaerder said. "Indeed, several patients displaying the same known sub-type of breast cancer can respond differently to a given drug. An epigenetic difference between the tumors of these patients might explain the difference observed in terms of treatment response. Therefore, DNA methylation profiling could help to refine the current breast cancer classification and thus might help to stratify patients within a particular sub-type both in terms of prognosis and prediction to treatment response."
"I think we can harness epigenetic information to improve cancer care in several ways," Dr Dedeurwaerder said. "Firstly, several lines of evidence suggest that epigenetic dysregulation occurs early during carcinogenesis and can be detected in bodily fluids. Therefore, DNA methylation markers could help to provide an earlier detection of the disease."
"Secondly, it has already been shown that DNA methylation markers might help to better stratify patients in terms of prognosis. Thirdly, such markers could also help to predict response to a given drug."
"Lastly, an epigenetic therapy of cancer, alone or in combination with conventional therapies, is conceivable," Dr Dedeurwaerder said. "Indeed, several drugs have been developed and several clinical trials have already shown promising results, in particular for leukemia."
"In this study, we have generated the largest and most comprehensive DNA methylation dataset for human breast tumor tissues," the researchers conclude. "By laying the ground for better understanding of breast cancer heterogeneity and improved tumor taxonomy, the precise epigenetic portraits drawn in our work should contribute to better management of breast cancer patients."
Commenting the study, which he was not involved in, Prof Fortunato Ciardiello, from Seconda Università di Napoli, Naples, Italy, noted that gene expression profiles by microRNA analysis have allowed to identify sub-groups of human breast cancers with different biological behaviors and eventually different prognosis.
"Now, for the first time, whole genome epigenetic analysis reveals, in a large number of human breast cancers, a series of sub-types which could help better define more homogeneous groups, which could be useful to select appropriate and more personalized therapeutic approaches."
INFORMATION: END
German researchers have identified an unexpected molecular marker that predicts how sensitive hard-to-treat triple-negative breast cancers are to chemotherapy.
Triple-negative breast cancers --which do not express the genes for estrogen receptor, or progesterone receptor and do not have Her2/neu overexpression or amplification-- are more aggressive than other forms of the disease and cannot be treated with endocrine or Her2 targeted therapies.
At the IMPAKT Breast Cancer Conference in Brussels, PhD student Carolin Huelsewig and Dr Cornelia Liedtke from Uniklinikum Muenster ...
Two multi-gene tests designed to predict the risk of disease progression and response to chemotherapy in breast cancer produce broadly similar results for high- and low-risk patients, but do not always agree in their predictions for those at intermediate risk, a new analysis shows.
In recent years, several genomic tests have been developed to provide prognostic information for breast cancer. Dr Catherine Kelly from Mater Misericordiae University Hospital, Dublin, Ireland, and colleagues in the USA examined the agreement in prediction results between two multi-gene assays ...
Measuring the transfer of tiny amounts of energy from one protein to another on breast cancer cells has given scientists a detailed view of molecular interactions that could help predict how breast cancer patients will respond to particular therapies.
At the IMPAKT Breast Cancer Conference in Brussels, Dr Gargi Patel from the Richard Dimbleby Department, King's College London, described cutting-edge research in which she and colleagues captured detailed information about protein interactions on cancer cells, and correlated that with established genetic markers for cancer ...
The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.
The results of a randomized trial in 45 patients with primary invasive breast cancer showed that the drug --which is currently used to treat arthritis and other painful conditions-- clearly induced an anti-tumor response at the molecular level.
"This is exciting because it means that a medication already used to treat other diseases may be efficient in the adjuvant treatment of breast cancer ...
Domenico Di Ceglie, Director of Training and Research at the Gender Identity Development Service at the Tavistock and Portman NHS Foundation Trust in London, commented: "These are important findings in the field of gender incongruence, which need to be replicated. The awareness of the presence of autistic features may help these young people to explore the reasons behind their perceptions, and help them make more informed decisions about treatment."
Emma Martin, who runs a Gender Identity Support and research group in Little Downham, UK, welcomed the new findings, and ...
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
The biosensor has been developed by researchers at the Virginia Institute of Marine Science (VIMS) and was tested in the Elizabeth River and Yorktown Creek which both drain into Virginia's Chesapeake Bay.
"Our biosensor combines the power of the immune system ...
Spine Surgeon LA, the leading spine surgery specialists in the state of California has recently launched their website at the URL www.spinesurgeonla.com
Spine Surgeon LA is a medical hub wherein they treat and address several different types of spine problems. These spine problems include: Bulging Disc, Herniated Disc, Spine Scoliosis, Pinched Nerve, Spine Stenosis, Bone Spurs, and Spine Tumors among others. In their new website, spinesurgeonla.com, you may click on these common spine problems and then get a chance to read some information about them so that you may ...
Deadly human fungal infections caused by certain strains of Aspergillus fungi appear to be developing resistance to current drug treatments at an alarming rate, say scientists.
University of Manchester researchers, working with colleagues in Newark, USA, have developed a new test that can not only better diagnose Aspergillus infection, but can also spot signs of antifungal resistance to azoles – the class of drugs used to treat patients with aspergillosis.
Using the new test, which uses direct molecular detection rather than culturing the fungus in a Petri dish, the ...
The recent nuclear accident in Fukushima Daiichi in Japan has brought the nuclear debate to the forefront of controversy. While Japan is trying to avert further disaster, many nations are reconsidering the future of nuclear power in their regions. A study by Behnam Taebi from the Delft University of Technology, published online in the Springer journal Philosophy & Technology, reflects on the various possible nuclear power production methods from an ethical perspective: If we intend to continue with nuclear power production, which technology is most morally desirable?
On ...
(WASHINGTON) -- Researchers in the Materials Science and Technology division of the Naval Research Laboratory have recently demonstrated electrical injection, detection and precession of spin accumulation in silicon, the cornerstone material of modern device technology, at temperatures up to 225 degrees Celsius. These results provide the first demonstration that spin accumulation in Si is viable as a basis for practical devices which meet the operating temperatures specified for commercial (85˚C), industrial (100˚C) and military (125˚C) applications. This ...
